Podcast
MLS Talk: Tom Caravela, Lusine Kodagolian
Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Summary
- Oncology therapy is becoming more expensive, challenging the affordability and sustainability of drug programs globally.
- Health technology assessment organizations use clinical trials for drug funding decisions, which may not reflect real-world outcomes.
- The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration is creating a framework for generating and using real-world evidence (RWE) for cancer drug funding in Canada.
- CanREValue consists of multiple stakeholders, including researchers, decision-makers, payers, patients, and caregivers.
- Five working groups focus on specific processes for RWE: Planning and Drug Selection, Methods, Data, Reassessment and Uptake, and Engagement.
- The framework aims to reassess cancer drugs, refine funding recommendations, and implement novel funding mechanisms for better clinical and economic outcomes.
New therapies for cancer are becoming increasingly more expensive, challenging the affordability and sustainability of public drug programs in Canada and around the world. While the cost increases of new cancer therapies are evident, the benefits are not always clear. In the Canadian cancer drug funding process, after receiving regulatory approval from Health Canada, organizations such as the pan-Canadian Oncology Drug Review (pCODR) at the Canadian Agency of Drugs and Technologies in Health (CADTH) and the Institute national d"excellence en santé et services sociaux (INESSS) in Quebec evaluate new cancer drugs and make funding recommendations to federal and provincial public payers. However, there is no policy infrastructure or framework in place for post funding reassessment of cancer drugs, leaving payers and policy decision-makers with limited opportunity to incorporate more mature evidence into funding decisions or to renegotiate prices with manufacturers based on evolving evidence and expanded use.
RWD, Canadian Real World Evidence, cancer drug, funding, framework
Related Topics
You May Also Like
MLS Talk: Tom Caravela, Lusine Kodagolian
Podcast
MSL Talk: Tom Caravela, Linda Traylor
Objection Handling for Field Medical Professionals
Article
Di Maria Jiang, Kelvin K. W. Chan, Raymond W. Jang, Christopher Booth, Geoffrey Liu, Eitan Amir, Robert Mason, Louis Everest, Elena Elimova
Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
Article
Yafang Huanga, Weiyi Xiongb, Jingwei Zhaoa, Wentao Lia, Li Mac, Hao Wua
Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD